Chronic HBV infection. Immunomodulation with levamisole in viremic HBeAg positive or Anti-HBe positive patients - A pilot study

Hepato-Gastroenterology

Volumn 46, Issue 30, 1999, Pages 3184-3188

  Krastev, Zahariy ^a   Jelev, Deian ^a   Antonov, Krasimir ^a   Alagozian, Victoria ^b   Kotzev, Iskren ^c  

^a UNIVERSITY HOSPITAL ALEXANDROVSKA   (Bulgaria)

^b MEDICAL UNIVERSITY OF PLOVDIV   (Bulgaria)

^c MEDICAL UNIVERSITY OF VARNA   (Bulgaria)

Author keywords

HbeAg; HBV; HBV DNA; Immunomodulation; Levamisole

Indexed keywords

ALPHA INTERFERON; AMINOTRANSFERASE; HEPATITIS B CORE ANTIGEN; HEPATITIS B(E) ANTIGEN; LEVAMISOLE; VIRUS DNA;

ADOLESCENT; ADULT; ARTICLE; ASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOMODULATION; MALE; NAUSEA; PRIORITY JOURNAL; SCHOOL CHILD; SEROCONVERSION; VIRUS REPLICATION;

EID: 0032786056     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. 1 Hoofnagle JH, Peters MG, Mullen KD, et al: Randomized, controlled trial of recombinant human a-interferon in patients with chronic hepatitis B. Gastroenterology 1988; 95:1318-1325.
2. 2 Di Bisceglie AM, Fong T-L, Friend MW, et al: A randomized, controlled trial of recombinant alpha-interferon therapy for chronic hepatitis B. Am J Gastroenterol 1993; 88:1887-1892.
3. 3 Wong DKH, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J: Effect of alpha - interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med 1993; 119:312-323.
4. 4 Carman WF, Jacyna MR, Hadziyannis S, Karayannis P, McGarvey MJ, Makris A, Thomas J: Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; ii:588-590.
5. 5 Bonino F, Brunette MR, Rizzetto M, Will H: Hepatitis B virus unable to secrete e antigen. Gastroenterology 1991; 100:1138-1141.
6. 6 Lok ASF, Hadziyannis SJ, Weller IVD, Karvountzis MG, Monjardino J, Karayannis P, Montano L Thomas H: Contribution of low level HBV replication to continuing inflammatory activity in patients with anti-HBe positive chronic hepatitis B virus infection. Gut 1984; 25:1283-1287.
7. 7 Fattovich G, Brollo L, Alberti A, Pontisso P, Giustina G, Realdi G: Long-term follow-up of anti-HBe-positive chronic active hepatitis B. Hepatology 1988; 8:1651-1655.
8. 8 Brunetto MR, Oliveri F, Rocca G, Criscuolo D, Chiaberge E, Capalbo M, David E, Verme G, Bonino F: Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen. Hepatology 1989; 10:198-202.
9. 9 Bonino F, Thomas HC: Prospects in the treatment of viral hepatitis. J Hepatol 1991; 13(Suppl 1):S1-S32.
10. 10 Fattovich G, Giustina G, Alberti A, Guido M, Pontisso P, et al: A randomized controlled trial of thymopentin therapy in patients with chronic hepatitis B J Hepatol 1994;21(3):361-366.
11. 11 Mutchnick MG, Lindsay KL, Schiff ER, Cummings GD, Appelman HD: Thymosin a1 treatment of chronic hepatitis B: a multicenter, randomized, placebo-controlled double blind study. Gastroenterology 1995; 108(Suppl):A1127. (Abstract)
12. 12 Chien RN, Liaw YF: Drug therapy in patients with chronic type B hepatitis. J Formos Med Assoc 1995; 94(Suppl. 1):S1-9.
13. 13 Vassilev M, Antonov K, Teochrov P, Krastev Z: Effects of low molecular weight glycoproteins in chronic hepatitis B. Hepato-Gastroenterol 1996; 43:883-886.
14. 14 Nilus R, Schentke U, Otto L, Teichmann W, Zipprich B, Schmidt W, Brugmann E, Busse HJ: Levamisole therapy in chronic hepatitis-results of a multicentric double blind trial. Hepato-Gastoenterol 1983; 30:90-92.
15. 15 Brunner J, Mucophat C: Immunomodulatory effects of levamisole. JAMA 1980; 176:1159-1162.
16. 16 Renoux G, Renoux M, Teller M, McMahon S, Guillaumin J: Potentiation of T-cell mediated immunity by levamisole. Clin Exp Immunol 1976; 25:288-296.
17. 17 Symoens J, Rosentahl M, De Brabander M, Goldstein G: Immunoregulation with Levamisole. In: Chedid L, Miescher PA, Mueller HJ, Eberhard M (Eds.). Immunostimulation. Belin-Heidelberg-New York: Springer-Verlag, 1980; pp. 195-214.
18. 18 Fattovich G, Cadrobbi P, Crivellaro C, Pronaro E, Alberti A, Realdi G: Virological changes in chronic hepatitis type B treated with levamisole. Digestion 1982; 25:131-137.
19. 19 Fattovich G, Brollo L, Pontisso P, Pornaro E, Rugge M, Alberti A: Levamisole therapy in chronic type B hepatitis-results of a double blind randomized trial. Gastroenterology 1986; 91:692-696.
20. 20 Bosch O, Moraleda G, Castillo I, Carreno V: Treatment of chronic hepatitis B with recombinant interferon alpha versus recombinant interferon alpha plus levamisole. J Hepatol 1993 19(3):437-441.
21. 21 Fattovich G, Giustina G, Brollo L, Guido M, Pontisso P, Noventa F, Alberti A: Therapy for chronic hepatitis B with lymphoblastoid interferon-alpha and levamisole. Hepatology 1992; 16(5):1115-1119.
22. 22 Ruiz-Moreno M, Garcia R, Rua MJ, Serrano B, Moraleda G, Feijoo E, Bartolome J, Ortiz F, Castillo I, Carreno V: Levamisole and interferon in children with chronic hepatitis B. Hepatology 1993; 18(2):264-269.
23. 23 Naumov MV, Lau JY, Daniels HM, Alexander GJ, Williams R: Detection of HBV DNA using a dioxigenin-labeled probe. A rapid technique without loss of sensitivity. J Hepatol 1991; 12:382-385.
24. 24 Naumov MV, Portmann BC, Tedder RS, Ferns B, Eddleston AL, Alexander GJ, Williams R: Detection of hepatitis B virus antigens in liver tissue. A relation to viral replication and histology in chronic hepatitis B infection. Gastroenterology 1990; 99(3):793-798.
25. 25 Dudley FJ, Giustino V, Sherlock S: Cell mediated immunity in patients positive for hepatitis-associated antigen. Br Med J 1972; 4:754-756.
26. 26 Eddlestone ALWF, Williams R: Inadequate antibody response to HBsAg or suppressor T cell defect in development of active chronic hepatitis. Lancet 1974; ii:1543-1545.
27. 27 Yuichi I, et al: Adjuvant immunochemotherapies versus chemotherapy in treatment of operable breast cancer. Recent Advances in Chemotherapy. Proceedings of the 18th International Congress of Chemotherapy. Stockholm 1993; pp. 806-807.
28. 28 Hajnzic T, et al: Role of levamisole in phagocytic activity in children with brain tumors. Recent Advances in Chemotherapy. Proceedings of the 18th International Congress of Chemotherapy. Stockholm 1993; p. 787.
29. 29 Hajnzic T, et al: Immunity in levamisole-treated children with acute lymphoblastic leukemia. Recent Advances in Chemotherapy - Proceedings of the 18th International Congress of Chemotherapy, Stockholm 1993; p. 788.
30. 30 Lygidakis NJ, Pothoulakis J, Konstantinidou AE, Spanos H: Hepatocellular carcinoma: surgical resection versus surgical resection combined with pre-and post-operative locoregional immunotherapy-chemotherapy. A prospective randomized study. Anticancer Res 1995; 15(2):543-550.
31. 31 Lygidakis NJ, Ziras N, Parissis J: Resection versus resection combined with adjutant pre-and post-operative chemotherapy-immunotherapy for metastatic colorectal liver cancer. A new look at an old problem. Hepato-Gastroenterol 1995; 42(2):155-161.
32. 32 Jablkowski M, et al: Prolonged viral hepatitis type B - assessment of the clinical status and selected immunologie parameters after the immunocorrection with levamisole. X International Congress of Liver Diseases. Basel 1995.
33. 33 Chadwick RG, Jain S, Cohen BJ, Scott GM, Thomas HC, Sherlock S: Levamisole therapy for HBsAg positive chronic liver disease. Scand J Gastroenterol 1980; 15:973-978.